| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| Efimosfermin alfa | LLF-580; BOS-580; GSK-6519754 | Phase 3 Clinical | Novartis Pharma Ag | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | 詳細 |
| Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Diabetes Mellitus; Liver Cirrhosis; Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| MWN-105 | MWN-105 | Phase 2 Clinical | Shanghai Minwei Biotechnology Co Ltd | Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | 詳細 |
| TQA-2225 | AP-025; TQA2225; TQA-2225 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| HEC-88473 | HEC-88473; HEC88473; APL-18881 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Diabetes Mellitus, Type 2; Hepatitis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | 詳細 |
| B-1344 | B-1344 | Phase 1 Clinical | Tasly Biomedical Co Ltd | Diabetes Mellitus, Type 2; Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| DMR-2301 | DMR-2301; DMR2301 | Phase 1 Clinical | Shanghai Duomirui Biotechnology Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease | 詳細 |
| ZT-003 | ZT003; ZT-003 | Phase 1 Clinical | Beijing QL Biopharmaceutical Co Ltd | Diabetes Mellitus; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity | 詳細 |
| AP-026 | TQA2226; AP026; AP-026; TQA-2226 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Diabetes Mellitus, Type 2; Hyperlipidemias; Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Overweight | 詳細 |